HM15275 vs UBT251
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Obesity
Shared mechanism: GLP-1/GIP/glucagon receptor (triple) · full Obesity pipeline
HM15275
Developed by Hanmi Pharmaceutical
NCT06481098 · Phase 1 · completed
The trial randomized participants against a matched placebo with full blinding, but its primary measures were safety and tolerability rather than a body-weight or metabolic efficacy outcome. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source. Its registered primary outcome on ClinicalTrials.gov is "Part A: Safety and Tolerability" (with 1 other safety or dose-finding measure). Its registered primary outcomes are safety, tolerability or dose-finding measures only, so the evidence grade is capped at weak.
Next expected readout: January 2027 · NCT07205900 (registry estimate)
Reported efficacy
Part A: Safety and Tolerability (Up to Day 29); Part B: Safety and Tolerability (Up to Day 57): Phase 1 single and multiple ascending dose study of HM15275: the single-dose part included 24 healthy volunteers (66.7% male, BMI 24.0 kg/m2) and the multiple-dose part 50 obese adults (62.0% male, BMI 33.3 kg/m2). The most common adverse events in HM15275 recipients were mild to moderate gastrointestinal symptoms, with no clinically significant changes in vital signs or laboratory parameters, and no serious adverse events or discontinuations due to treatment-related adverse events in either part.
Result source: NCT06481098
UBT251
Developed by Novo Nordisk under a licence from United Bio-Technology (Hengqin)
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: December 2026 · NCT07785934 (registry estimate)
No aligned efficacy figure on record for this race.
Results for Obesity
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | HM15275 | UBT251 |
|---|---|---|
| Body weight, % change | —Not reported | —Trial running · NCT07806851 |
| Weight loss of 5% or more | —Not reported | —Trial running · NCT07806851 |
| Weight loss of 10% or more | —Not reported | —Trial running · NCT07806851 |
| Waist circumference, change (cm) | —Not reported | —Trial running · NCT07806851 |
Body weight, % change
- HM15275
- —Not reported
- UBT251
- —Trial running · NCT07806851
Weight loss of 5% or more
- HM15275
- —Not reported
- UBT251
- —Trial running · NCT07806851
Weight loss of 10% or more
- HM15275
- —Not reported
- UBT251
- —Trial running · NCT07806851
Waist circumference, change (cm)
- HM15275
- —Not reported
- UBT251
- —Trial running · NCT07806851
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
HM15275: no structured comparison results are available for Obesity.
UBT251: no structured comparison results are available for Obesity.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: HM15275's landscape · UBT251's landscape